Key Takeaways
- Six-quarter slump breaks: The company returned to positive performance, driven by an acceleration in international formulations across both regulated and emerging markets.
- Domestic business muted by seasonality: Anti-infectives and respiratory segments took a significant hit, masking underlying prescription growth that signals fundamental brand strength.
- Subsidiary losses weigh on consolidated health: FPP was hit by extraordinary expired-product costs and poor mix, while Warren Remedies carries API validation costs with no offsetting sales yet.
- Ophthalmic hive-off sharpens focus: The sale of the small India and Africa ophthalmic business to Sunway lets management concentrate on core ethical brands, though it raises a liquidity question management firmly denied.
- What to watch next quarter: Whether the domestic prescription-to-sales gap closes as summer seasonality kicks in, the pace of debt reduction against a ₹140 cr annual target, and any progress on resolving the sterile plant situation.
Domestic Business: Prescriptions Outrun Sales
- Seasonal drag on primary sales: Anti-infectives and respiratory products gave a significant hit in Q4 because the season did not support performance; March rains delayed the summer kick-in for products like the urinary alkalizer Cital.
- Prescription strength hidden by booking gap: Product-wise prescriptions show good growth, but primary sales in Q4 are often low due to field staff morale and annual target dynamics; stomatologicals saw IQVIA down only 8% while primaries fell 20%, yet prescriptions on those products are in high growth.
- Cital as a case study: Internal performance down 10% for the quarter and QoQ down 1%, but IQVIA and prescriptions are growing, with less than 30 days of stock in the market per Pharmarack.
- New launches contribute meaningfully: Q4 new launches contributed over ₹2 crore, with the full year at ₹20 crore; key products include Cital-PM6, Dropizin, Drotitec M, and the Cyclopam AC suspension extension.
- Growth concentrated in low-base categories: Cardiac and anti-diabetic growth is attributed to a very low base, while urologicals were impacted by seasonality.
- Rexidin-M Forte gel milestone: As of January 2026 and on a max basis for March 2026, it became the most prescribed stomatological brand in the market; the company also overtook Pfizer to become the 20th most prescribed company by prescription count.
Aditi Panandikar: "It gives me great joy to announce that after almost six quarters, we are in positive in this quarter for performance."
International Formulations: The Quarter's Engine
- US growth driven by site transfers and solids: Sterile products that were site-transferred contributed ₹12 crore, while a substantial solid oral base filled out the rest; the same quarter last year saw Plant-1 in Goa and Baddi 3 undergoing master manufacturing cycles, which constrained supply.
- US pipeline diversifies beyond sterile: ANDA approvals for liquid orals Brivaracetam and Lacosamide were received; management plans to launch liquid orals in the US and Europe in the coming year, targeting a less crowded space.
- Europe base contract manufacturing to scale: Better margins are expected as plants complete MMP scale-ups; almost all customer approvals for MMP are in, except a very small paracetamol livery in Baddi 1.
- Clarity Pharma business held back deliberately: Management is holding back when market prices are not opportune, prioritizing margin capture over volume.
- Emerging markets confidence high: Management expressed high confidence in Eastern Africa and French West Africa for the next 2–3 years; toothpaste exports to South Africa have commenced at ₹37 lakhs.
Aditi Panandikar: "The whole purpose of being on ground in U.K. is to be able to get more margin and not lose it so, if we see that the market is not opportune on price front then we hold."
Subsidiary Health: FPP and Warren Remedies
- FPP negative net worth jump explained: The ₹50 crore increase in FPP negative net worth (from ₹25 crore to ₹82 crore) is because the consolidated number includes both FPP and Warren, not FPP alone.
- FPP profitability hit by one-offs and mix: Extraordinary costs on expired products of almost ₹4 crore and a poor product mix drove COGS on Q4 sales extraordinarily high; some products have low margins and shelf stock adjustments were needed.
- Warren Remedies API plant a cost center: The API CAPEX is done and operating costs are running, but no sales are possible because most products are still under validation and not approved from that site.
- Warren OTC investment phase continues: The OTC business is being supported with advertising for at least 3 years; the toothpaste block is efficient (5,000 kg batches with 5 people) but only 1 of 4 planned lines is installed.
- FPP extraordinary cost impact should reduce going forward.
Aditi Panandikar: "It is the API CAPEX done and the operating cost at API level from where we are really not able to sell anything right now because most products are under validation."
Balance Sheet & Liquidity
- Receivables stretched by international mix: International business, especially emerging markets, carries longer credit periods, driving up receivables days; management did not provide an aging breakdown or shipment-vs-receipt percentage when asked. [5–6]
- Interest cost spike from forex loss: Consolidated interest cost was materially up, including a ~₹24 crore exchange loss on a foreign currency (ECB) loan of 10 million euros; the loss is notional unless the war continues. [8–9]
- Debt reduction commitment: Management is targeting repayment of ₹140 crore per year for the next 3 years, with an aim to prepay a little more than that; tight control on CAPEX is now in place with no major CAPEX planned in the next 2 years.
- MSME dues to be settled shortly: Management expressed confidence that within a week they should be able to settle MSME dues.
- Idle land parcel held for sale: A land parcel valued at ₹23 crore is classified as held for sale and being marketed.
Strategic Moves & Plant Resolution
- Ophthalmic business hive-off: Indoco entered into an agreement to hive off its ophthalmic business in India and Africa to Sunway; management stated the division was small (₹37 cr India primary sales) and the company was the 13th player in a market where smaller, focused companies get a lead.
- Liquidity question denied: When asked if the hive-off was done to tide over a liquidity situation, management answered "Absolutely not," framing it as a move to give the brands the attention they deserve and let Indoco focus on core ethical business strengths.
- Sterile plant resolution still pending: The company continues to spend significantly on the sterile site and is trying to resolve the plant situation as soon as possible; for key sterile products, second sites have been added and some sterile sales for the US in Q4 were billed from those sites.
- Future approvals at risk: What will really be impacted if the plant situation does not get resolved is future approvals; management is trying to hasten USFDA approval by varying the site of a product from Patalganga to audit, but cannot promise this will work.
- Portfolio optimization complete for now: At this point, no more identified opportunities exist for portfolio rejig in the India business beyond what has already been done.
Aditi Panandikar: "This move was made in the interest of our wonderful brands and portfolios which should now get the requisite attention they deserve and therefore grow. This hive off would also help us at Indoco focus on areas of strength and those which are our core areas for growing the ethical business."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Debt reduction | Repay ₹140 crore per year, aim to prepay a little more | Next 3 years |
| CAPEX restraint | No major CAPEX planned | Next 2 years |
| MSME dues settlement | Confident of settling dues | Within a week of the call |
| India business growth | Expected in line with IPM | Ongoing |
| Warren API turnaround | Reg market approval expected | About one more year |
| Warren API near-term | Turnaround likely to take a couple more quarters | Couple of quarters |
| US/Europe liquid oral launches | Launch liquid orals in less crowded space | Coming year |
| FPP extraordinary cost impact | Should reduce going forward | Forward-looking |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Standalone net revenue | ₹429.1 cr, +25.8% YoY and +10.1% QoQ |
| Consolidated net revenue | ₹455.9 cr, +18.8% YoY and +5% QoQ |
| Standalone EBITDA margin | 14.7% (₹63 cr), vs 1% (₹3.5 cr) YoY and 6.6% (₹25.9 cr) QoQ |
| Consolidated EBITDA margin | 10.9% (₹49.7 cr), vs -0.2% (-₹0.8 cr) YoY and 7.3% (₹31.5 cr) QoQ |
| Domestic formulation revenue | ₹173.9 cr, vs ₹185.1 cr YoY |
| International formulation revenue | ₹214.7 cr, +94.6% YoY |
| Regulated markets revenue | ₹140.1 cr, +78.3% YoY |
| US business revenue | ₹54.6 cr, +77.5% YoY |
| Europe revenue | ₹78.6 cr, +68.7% YoY |
| South Africa, Australia and New Zealand revenue | ₹69.2 cr, vs ₹12.2 cr YoY |
| Emerging markets revenue | ₹74.6 cr, +134% YoY |
| API business revenue | ₹31.5 cr, -23% YoY |
| Services revenue (AnaCipher CRO and Indoco Analytical Solutions) | ₹89.5 cr, +65.3% YoY |
| Consolidated debt | ~₹960 cr, long-term ₹620 cr, short-term ₹344 cr; flat vs March '25 |
| Debt repayment commitment for FY27 | ₹140 cr, with similar amounts each year for next 3 years |
| Average interest rate on borrowings | 8.5% to 9% |
| Forex loss on ECB loan | ₹24 cr impact on finance cost |
| OTC (Warren) revenue | ₹27.4 cr for Q4; ₹120 cr for full year |
| New launch contribution (India) | >₹2 cr for Q4; ₹20 cr for full year |
| Ophthal division India primary sales (full year) | ₹37 cr |